Revisiting: Food effects on oral incretin absorption: what is documented

Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable.

Food effects on oral incretin, from the point of view of someone who has read the documentation and is still stuck.

Saying which parts I have understood so that nobody wastes time re-explaining them, and where exactly the understanding stops.

The opening post answers the question as asked. The question underneath it is different.

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

Coming back to post #3, because the follow-up matters more than the original answer.

Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

Clear enough that I do not think I have a follow-up, which is unusual.

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

Two people can read the same figure differently here and both be reasonable.

Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.

Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.

I would treat that as a working assumption and revisit it.

The arithmetic in post #8 is right; the assumption feeding it is the part to check.

Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.